Newsroom Read More with Amanda Frost VIEW MORE VIEW MORE FROM JC SCOTT Katie Payne Senior Vice President, Public Affairs kpayne@pcmanet.org Greg Lopes Vice President, Public Affairs glopes@pcmanet.org 202-756-5713 Mike Baldyga Director, Public Affairs mbaldyga@pcmanet.org 202-756-5714 FOR YOUR INFORMATION The
Misguided Legislation Targets Pharmacy Benefits That Save Employers and Patients an Average of $1,000 Per Person Each Year and Undermines Market Forces in Health Care In case you missed it, leading economic experts and competition watchdogs have overwhelmingly expressed concern
With the recent launch of a new adalimumab biosimilar, the U.S. biosimilar market is becoming more competitive, increasing the potential for these more affordable options to play a critical role in helping to lower prescription drug costs for Americans. As biosimilar competition
As a reminder, the U.S. House of Representatives Committee on Oversight and Reform previously found, in a 2021Â report, that PBM-negotiated rebates are not correlated with the list prices set by drug companies. The report also finds that âdrug companies have
(Washington, D.C.) â The Pharmaceutical Care Management Association (PCMA) today released a new, first-of-its-kind, progress report on the work PCMA member pharmacy benefit companies are doing to deepen the industryâs commitment to promote health equity and reduce health disparities. This
(Washington, D.C.) â The Pharmaceutical Supply and Payment Chain Coalition issued the following statement in response to the Administrationâs February 24, 2021, Executive Order on Americaâs Supply Chains. âAs representative organizations of Americaâs pharmaceutical supply and payment chain, including prescription and over-the-counter
As independent pharmacies conduct a âFly-Inâ in Washington D.C this week, they will undoubtedly double-down on support for policies targeting pharmacy benefit companies that would have profound negative consequences for employers, taxpayers, and patients. Itâs important for lawmakers to consider
In case you missed it, a new article in Inside Health Policy reported that âInvestors for eight major drug companies will vote throughout the spring on 11 proposals aimed at reducing the use of common drug patent practices and pharmaceutical lobbying activities
©2024 PCMA. All Rights Reserved.
